January 4, 2018 / 1:47 PM / Updated 9 minutes ago BRIEF-ImmunoGen Announces First Patient Dosed In Phase 1 Study Of IMGN632 For Hematological Malignancies Reuters Staff 1 Min Read 
Jan 4 (Reuters) - ImmunoGen Inc: 
* IMMUNOGEN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 STUDY OF IMGN632 FOR HEMATOLOGICAL MALIGNANCIES Source text for Eikon: Further company coverage: